Please login to the form below

Not currently logged in
Email:
Password:

Forxiga

This page shows the latest Forxiga news and features for those working in and with pharma, biotech and healthcare.

PMCPA takes AZ to task over asthma drug press release

PMCPA takes AZ to task over asthma drug press release

company in Amsterdam last November relating to SGLT2 inhibitor diabetes drugs and specifically its Forxiga (dapagliflozin) product.

Latest news

  • AZ data suggest SGLT2 inhibitors can reduce heart failure risk AZ data suggest SGLT2 inhibitors can reduce heart failure risk

    Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance. Real-world evidence has shown that treatment with the newer SGLT2 inhibitor class of diabetes drug can dramatically cut ... Now, AZ's study suggests that benefit is

  • Merck & Co and Pfizer take aim at diabetes with trio of new drugs Merck & Co and Pfizer take aim at diabetes with trio of new drugs

    The first SGLT2 inhibitor to be approved in the US was Johnson &Johnson's Invokana (canagliflozin) in 2013, while in Europe it was AstraZeneca's Forxiga/Farxiga (dapagliflozin) the previous year. ... J&J's Invokana franchise brought in $1.4bn in sales

  • New Jardiance label could boost sales by $1.7bn, says analyst New Jardiance label could boost sales by $1.7bn, says analyst

    Another SGLT1 inhibitor - Bristol-Myers Squibb/AstraZeneca's Forxiga/Farxiga (dapagliflozin) - is also in a cardiovascular outcomes trial that is not due to generate results until 2019.

  • AstraZeneca's Forxiga set to be recommended by NICE AstraZeneca's Forxiga set to be recommended by NICE

    Currently in the final stages of consultation, the guidance endorses the use of AstraZeneca's SGLT2 inhibitor Forxiga (dapagliflozin) in patients already taking two drugs for blood sugar control without success. ... The firm is looking to expand Forxiga

  • AZ looks beyond diabetes with Forxiga trials AZ looks beyond diabetes with Forxiga trials

    Will investigate dapagliflozin in kidney disease and heart failure.  . AstraZeneca has started a clinical trial programme to try to extend the use of its diabetes drug Forxiga into kidney disease and ... SGLT2 inhibitor Forxiga (dapagliflozin) is one of

More from news
Approximately 15 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The potential

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics